• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by 8i Acquisition 2 Corp.

    5/19/23 5:19:18 PM ET
    $LAX
    Get the next $LAX alert in real time by email
    NT 10-Q 1 formnt10-q.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12b-25

     

      NOTIFICATION OF LATE FILING

    SEC FILE

    NUMBER

    001-40678

       
       
       

    CUSIP NUMBER

    G3142E105

       

     

    (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR

     

      For Period Ended: March 31, 2023
       
      ☐ Transition Report on Form 10-K
      ☐ Transition Report on Form 20-F
      ☐ Transition Report on Form 11-K
      ☐ Transition Report on Form 10-Q
      ☐ Transition Report on Form N-SAR
       
      For the Transition Period Ended:________________________

     

    Read attached instruction sheet before preparing form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
     

    PART I - REGISTRANT INFORMATION

     

    Full Name of Registrant
    EUDA Health Holdings Limited
    Former Name if Applicable
    8i Acquisition 2 Corp.
    Address of Principal Executive Office (Street and Number)
    1 Pemimpin Drive #12-07

    City, State and Zip Code

     

    One Pemimpin Singapore 576151

     

     

     

     

     

     

    PART II

    RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

    (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    ☐ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR or From N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III

    NARRATIVE

     

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    EUDA Health Holdings Limited (formerly known as 8i Acquisition 2 Corp.) ( the “Company”) has determined that it is unable to file with the Securities and Exchange Commission (the “SEC”) its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 (the “Form 10-Q”) within the prescribed time period without unreasonable effort or expense due to the reasons described below.

     

    PART IV

    OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

    Wei Wen Kelvin Chen   +65   6268-6821
    (Name)   (Area Code)   (Telephone Number)

     

    (2)

    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months (or for such shorter) period that the registrant was required to file such reports) been filed? If answer is no, identify report(s).

    ☐ Yes ☒ No

      Annual Report on Form 10-K for the fiscal year ended December 31, 2022

     

     

     

     

    (3)

    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

    ☒ Yes ☐ No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    On November 17, 2022, the Company consummated the previously announced business combination contemplated by the Share Purchase Agreement (the “SPA”) between 8i Acquisition 2 Corp., a British Virgin Islands business company (“8i”), EUDA Health Limited, a British Virgin Islands business company (“EHL”), Watermark Developments Limited, a British Virgin Islands business company (“Watermark” or the “Seller”), and Kwong Yeow Liew, dated April 11, 2022 and amended May 30, 2022, June 10, 2022, and September 7, 2022. As contemplated by the SPA and described in the section titled “Proposal 1 —The Business Combination Proposal” beginning on page 107 of the definitive proxy statement dated October 13, 2022 (as amended on November 7, 2022 and November 9, 2022, the “Proxy Statement”) and filed by 8i with the SEC, a business combination between 8i and EHL was effected by the purchase by 8i of all of the issued and outstanding shares of EHL from the Seller (the “Share Purchase”), resulting in EHL becoming a wholly owned subsidiary of 8i. In addition, in connection with the consummation of the Share Purchase, 8i has changed its name to “EUDA Health Holdings Limited.” The transactions contemplated under the SPA relating to the Share Purchase are referred to as the “Business Combination.”

     

    As a result of the Business Combination, the Company anticipates that its results of operations for the first quarter ended March 31, 2023 when filed in the Form 10-Q will reflect significant changes from the first quarter ended March 31, 2022.

     

    Forward-Looking Statements

     

    This Form 12b-25 contains forward-looking statements, including statements about the financial condition, results of operations, earnings outlook and prospects of the Company. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking.

     

    The forward-looking statements are based on the current expectations of the Company’s management and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those discussed and identified in public filings made with the SEC by the Company.

     

     

     

     

      EUDA Health Holdings Limited  
      (Name of Registrant as Specified in Charter)  

     

    Has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: May 19, 2023 By: /s/ Wei Wen Kelvin Chen
      Name: Wei Wen Kelvin Chen
      Title: CEO

     

    INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

     

      ATTENTION  
       
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     

    Get the next $LAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LAX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chen Wei Wen Kelvin

    4 - EUDA Health Holdings Ltd (0001847846) (Issuer)

    6/20/23 3:19:26 PM ET
    $LAX

    SEC Form 3: New insider Wong Kongyew claimed no ownership of stock in the company

    3 - EUDA Health Holdings Ltd (0001847846) (Issuer)

    6/8/23 8:31:59 PM ET
    $LAX

    SEC Form 4 filed by Chen Wei Wen Kelvin

    4 - EUDA Health Holdings Ltd (0001847846) (Issuer)

    5/26/23 8:42:17 AM ET
    $LAX

    $LAX
    SEC Filings

    View All

    SEC Form 6-K filed by 8i Acquisition 2 Corp.

    6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

    1/22/24 9:30:30 PM ET
    $LAX

    SEC Form 6-K filed by 8i Acquisition 2 Corp.

    6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

    1/17/24 6:10:06 AM ET
    $LAX

    SEC Form 6-K filed by 8i Acquisition 2 Corp.

    6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

    12/29/23 5:03:20 PM ET
    $LAX

    $LAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    8i Acquisition 2 Corp. and EUDA Health Ltd Complete Business Combination

    Singapore, Nov. 23, 2022 (GLOBE NEWSWIRE) -- 8i Acquisition 2 Corp. (the "Company" or "LAX") (NASDAQ:LAX), a publicly traded special purpose acquisition company, today announced the completion of its business combination (the "Business Combination") with EUDA Health Ltd ("EUDA Health"), a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patient experience by delivering improved outcomes through personalized healthcare. The combined company will operate under the name "EUDA Health Holdings Limited" (NASDAQ:EUDA) and will be led by Founder and Chief Executive Officer Dr. Kelvin Chen. Commencing at the open of trading on N

    11/23/22 4:32:15 PM ET
    $LAX

    8i Acquisition 2 Corp. and EUDA Health Limited Complete Business Combination

    Singapore, Nov. 17, 2022 (GLOBE NEWSWIRE) -- 8i Acquisition 2 Corp. (the "Company" or "LAX") (NASDAQ:LAX), a publicly traded special purpose acquisition company, today announced the completion of its business combination (the "Business Combination") with EUDA Health Limited ("EUDA Health"), a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patient experience by delivering improved outcomes through personalized healthcare. The combined company will operate under the name "EUDA Health Holdings Limited" and will be led by Founder and Chief Executive Officer Dr. Kelvin Chen. Commencing at the open of trading on November 18, 202

    11/17/22 5:23:47 PM ET
    $LAX

    8i Acquisition 2 Corp. Announces Approval of Business Combination and Ability of Shareholders to Withdraw Ordinary Shares Tendered for Redemption

    Singapore, Nov. 10, 2022 (GLOBE NEWSWIRE) -- 8i Acquisition 2 Corp. (NASDAQ:LAX, the "Company"))), a special purpose acquisition company, announced today that all proposals presented to shareholders at the special meeting of shareholders held on November 10, 2022 at 10:00 a.m. Eastern Time relating to the Company's business combination with EUDA Health Limited were approved by shareholders. Holders of Company's ordinary shares that elected to redeem shares in connection with the Company's special meeting of shareholders may withdraw such redemption requests by no later than 5:00 p.m. Eastern Time on November 11, 2022. Based on a total of 8,195,770 ordinary shares tendered for redemption in

    11/10/22 4:01:00 PM ET
    $LAX

    $LAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by 8i Acquisition 2 Corp. (Amendment)

    SC 13D/A - EUDA Health Holdings Ltd (0001847846) (Subject)

    5/26/23 8:44:16 AM ET
    $LAX

    SEC Form SC 13G/A filed by 8i Acquisition 2 Corp. (Amendment)

    SC 13G/A - EUDA Health Holdings Ltd (0001847846) (Subject)

    2/14/23 10:13:57 AM ET
    $LAX

    SEC Form SC 13G/A filed by 8i Acquisition 2 Corp. (Amendment)

    SC 13G/A - EUDA Health Holdings Ltd (0001847846) (Subject)

    2/7/23 4:59:19 PM ET
    $LAX